Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Immunization Strategy 2017-2022


Foreword
 
There have been many transformations to the NIP inthe recent years. New vaccines wereadded to the vaccination schedule, the cohorts served by the public sector kepton expandingsince the onset of the Syrian crisis, measures to consolidatethe vaccine purchasing arrangements were adopted,and there wasa leveraging up ofthe vaccinovigilanceand its effective management.In 2016, the Ministryof health in Lebanon decided that it was the time to take stock, constructon the current NIP strengthsand achievements andidentify areas for further improvement. A strategy for the NIP for 2016-2020 wasenvisagedin agreementwith the development partners. A detailed situation analysis assessment was initiatedin October 2015 in two stages: at the initial stage, the country and health system contexts were analyzed, and immunization system performance was measured. In the second stage, a framework was developed in consultations with key stakeholders to define gaps in the evidence. Immunization coverage evaluation survey was conducted in 2016 and fed into filling the lacunas in information.

The present document expresses the country vision, goals and priorities of the national immunization program. It relies on a careful examination of the situation analysis, an assessment of the enablers and challenges facing the immunization services and defines the national immunization strategies addressing these contests. The strategies were formulated as informed choices across more than one solution deemed most feasible and efficient considering the country context.

The document is structured in three sections:

Section 1“Situational analysis” presents briefly the organization and operation of the national immunization program as well as the recent achievements and remaining challenges,

Section 2 “Conceptual framework” describes the future vision of the country in regards to vaccine preventable diseases, the long term goals to be achieved and the more specific results –immunization system objectives and targets for 2020,

Section 3 defines the Strategies to address the bottlenecks and achieve immunization system objectives by 2020. Most of strategies (so called “immunization system specific” ones) are presented by relevant health system blocks.The focus of the NIP Strategy, is to assistthe MOPH to meet international goals set by the World Health Organization (WHO) under the Global Immunization Vision and Strategy (GIVS). The Strategy articulates action areas to conserve the successful achievements of the last years, built on the current favoring momentum and propose solutions for the drawbacks

The Strategy comprises nineStrategic Priority Areas to complement and strengthen the NIP.

The matrix (Figure 2) in Annexesshows expected results of the immunization system development strategies by health system building blocks and links them to the root causes (weaknesses and treats) identified during the system analysis...
    ...
    99
    ...
ATC Name B/G Ingredients Dosage Form Price
L02BG06 EXEMESTANE G Exemestane - 25mg 25mg Tablet, film coated 1,222,897 L.L
M01AB16 LOFLAM G Aceclofenac - 100mg 100mg Tablet 767,334 L.L
N01BB02 LIDOCAINE- ORBUCELL G Lidocaine HCl - 2% 2% Injectable solution 1,787,950 L.L
N03AX11 TOPIRAMATE ARROW G Topiramate - 50mg 50mg Tablet, film coated 765,990 L.L
N05CD08 MIDAZOLAM NORMON. G Midazolam - 5mg/5ml 5mg/5ml Injectable solution 618,168 L.L
P02CA03 ANDAZOL G Albendazole - 200mg 6 Tablet, film coated 302,365 L.L
V03AC03 DEFEROXAL 360 G Deferasirox - 360mg 360mg Tablet, film coated 18,834,070 L.L
A02BC02 PANTOMAX G Pantoprazole (sodium sesquihydrate) - 40mg 40mg Tablet, enteric coated 1,381,470 L.L
B05CX01 SOLUFLEX DEXTROSE 5% INJECTION, USP G Glucose - 5% 5% Injectable solution 185,018 L.L
C09CA04 ANDARAN G Irbesartan - 300mg 300mg Tablet, film coated 940,435 L.L
C10AA07 PMS-ROSUVASTATIN G Rosuvastatin (calcium) - 10mg 10mg Tablet 564,414 L.L
D10AD03 DIFADERM G Adapalene - 0.3% 0.3% Gel 952,208 L.L
G04BE08 TADALAFIL BIOGARAN G Tadalafil - 5mg 5mg Tablet, coated 3,369,013 L.L
J01CR05 PRIZMA G Piperacillin (sodium) - 4g, Tazobactam (sodium) - 0.5g Injectable powder for solution 913,813 L.L
J01MA02 ESTECINA 200MG G Ciprofloxacine (lactate) - 200mg/100ml 200mg/100ml Injectable solution 32,190,251 L.L
L02BG06 EXEMESTANE ARROW G Exemestane - 25mg 25mg Tablet, film coated 3,386,483 L.L
M01AB55 DIFEN FLEX G Diclofenac sodium - 50mg, Pridinol mesylate - 4mg Tablet, film coated 575,165 L.L
N01BB02 LIDOCAINE PANPHARMA 2% G Lidocaine (HCl) - 20mg/ml 2% Injectable solution 3,398,578 L.L
N03AX11 TOPIRATE 50 BENTA G Topiramate - 50mg 50mg Tablet, film coated 1,407,835 L.L
N05CD08 MIDAZOLAM PANPHARMA G Midazolam - 5mg/5ml 5mg/5ml Injectable solution 697,454 L.L
A02BC02 PANTOVER G Pantoprazole (sodium sesquihydrate) - 40mg 40mg Tablet, enteric coated 739,113 L.L
B05CX01 7.5% DEXTROSE INJECTION USP G Dextrose monohydrate - 7.5% 7.5g/100ml Injectable solution 202,256 L.L
C09CA04 CONVERIUM G Irbesartan - 300mg 300mg Tablet 585,915 L.L
C10AA07 ROSUCOR G Rosuvastatin (calcium) - 10mg 10mg Tablet, film coated 487,623 L.L
G04BE08 TADALAGEN G Tadalafil - 5mg 5mg Tablet, film coated 1,766,193 L.L
J01CR05 TAZOBACT G Piperacillin sodium - 4g, Tazobactam (sodium) - 500mg Injectable powder for solution 783,460 L.L
J01MA02 LADININ G Ciprofloxacine (lactate) - 200mg/100ml 200mg/100ml Injectable solution 892,591 L.L
L02BG06 EXEMESTANE BGR G Exemestane - 25mg 25mg Tablet, coated 4,479,027 L.L
M01AB55 DIFEN FLEX G Diclofenac sodium - 75mg, Pridinol mesylate - 2.2mg Injectable solution 1,131,515 L.L
N01BB02 LIDO-CARE G Lidocaine - 2% 2% Injectable solution 100,788 L.L
    ...
    99
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025